Amneal Pharmaceuticals, Inc. (AMRX) financial statements (2021 and earlier)

Company profile

Business Address
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

Current Assets
Cash, cash equivalents, and short-term investments151213 
Cash and cash equivalents151213 
Restricted cash and investments25 
Inventory, net of allowances, customer advances and progress billings381457 
Prepaid expense3538 
Contract with customer, asset12
Other undisclosed current assets441 
Total current assets:1,2101,287 
Noncurrent Assets
Finance lease, right-of-use asset61
Operating lease, right-of-use asset70
Property, plant and equipment478544 
Intangible assets, net (including goodwill)1,8022,081 
Intangible assets, net (excluding goodwill)1,3831,655 
Other noncurrent assets4468 
Other undisclosed noncurrent assets 373 
Total noncurrent assets:2,4563,066 
TOTAL ASSETS:3,6664,353 
Current Liabilities
Accounts payable and accrued liabilities, including:507514 
Accounts payable103115 
Accrued liabilities7766 
Employee-related liabilities3677 
Taxes payable9  
Other undisclosed accounts payable and accrued liabilities283257 
Due to related parties618 
Other undisclosed current liabilities150 
Total current liabilities:550554 
Noncurrent Liabilities
Long-term debt and lease obligation2,6092,670 
Long-term debt, excluding current maturities2,6092,631 
Capital lease obligations39 
Liabilities, other than long-term debt4039 
Other liabilities4039 
Other undisclosed noncurrent liabilities120194 
Total noncurrent liabilities:2,7692,903 
Total liabilities:3,3193,456 
Stockholders' equity
Stockholders' equity attributable to parent, including:232505 
Common stock  0
Additional paid in capital607530 
Accumulated other comprehensive loss(0)(8) 
Accumulated deficit(378)(21) 
Receivable from shareholders or affiliates for issuance of capital stock  (0)
Other undisclosed stockholders' equity attributable to parent33 
Stockholders' equity attributable to noncontrolling interest115392 
Total stockholders' equity:347896 

Income statement (P&L) ($ in millions)

Cost of revenue
(Cost of Goods and Services Sold)
Other undisclosed gross profit(126)  
Gross profit:353716 
Operating expenses(602)(533) 
Other undisclosed operating loss (203) 
Operating loss:(249)(20) 
Nonoperating income (expense)28(183) 
Investment income, nonoperating7(3) 
Foreign currency transaction loss, before tax(5)(20) 
Interest and debt expense(6)(6) 
Loss from continuing operations before equity method investments, income taxes:(227)(209) 
Other undisclosed income from continuing operations before income taxes66 
Loss from continuing operations before income taxes:(220)(203) 
Income tax expense (benefit)(383)1 
Net loss:(604)(201) 
Net income attributable to noncontrolling interest24233 
Other undisclosed net income attributable to parent 149 
Net loss attributable to parent:(362)(20) 
Preferred stock dividends and other adjustments (1) 
Net loss available to common stockholders, diluted:(362)(21) 

Comprehensive Income ($ in millions)

Net loss:(604)(201) 
Comprehensive loss:(604)(201) 
Comprehensive income, net of tax, attributable to noncontrolling interest23236 
Other undisclosed comprehensive income, net of tax, attributable to parent19142 
Comprehensive loss, net of tax, attributable to parent:(353)(23) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: